Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

WaferGen Biosystems  (Stock symbol: WGBS ) Acquired by Takara Bio (2016 $ 50,000,000 )

34700 Campus Drive
Fremont, CA 94555
USA
(877-923-3746)
Website Company Summary Management Team
Management

CEO: Rolland Carlson (5/31/2015); Ivan Trifunovich (3/12/2012)
President/COO/Operations: Keith Warner (8/18/2014)
Finance: Michael Henighan (8/18/2014)
Technology: Jude Dunne (7/31/2010) ; Syed Husain (10/31/2009) ; David Gelfand (2007); Victor Joseph
Sales/Marketing: Gordon Pinkerton
Board

Outside board: (May no longer be on the board) R. Dean Hautamaki (Florida State University College of Medicine Assistant Professor) Makoto Kaneshiro (CSK Venture Capital Executive Director) Robert A. Schueren (IntegenX CEO) William McKenzie (PerkinElmer VP GM Molecular Diagnostics);  Joel Kanter (Windy City President)
Advisory board: Steven Bodovitz (VioInsights) Keith Bostian (Microcide Pharmaceuticals Founder) Michael Fero (Stanford Functional Genomics Institute) Jungho Kim (University of Maryland Associate Professor) J. Ramachandran (GangaGen CEO) Krishna Saraswat (Stanford University Professor) Mahendar Sunkara (University of Louisville Associate Professor) Nelson Teng (Stanford University Associate Professor) Bruce Wooley (Stanford University Professor) Ian Young (Delft University of Technology Professor)
Former outside board: Alnoor Shivji (WaferGen Biosystems Former CEO) Robert J. Hariri (Celgene Cellular Therapeutics Former CEO) Timothy J. Triche (University of Southern California Professor) Scott R. Davidson (Great Point Partners Managing Director) Joseph F. Pesce (Great Point Partners Managing Director) Robert C. Coradini (Johnson & Johnson Consumer Group of Companies President, New Ventures)
Company

Business description: WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8™ Single-Cell System is a first of its kind system that can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing. The system has demonstrated unbiased isolation of single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel singleplex PCR for one-step target enrichment and library preparation for clinical NGS. The Apollo 324™ system can be used to process DNA and RNA from clinical samples to next generation sequencing ready libraries. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.
Customers include: Harvard UniversityNASAUniversity of Southern California;  Abbott Labs;  Mayo Clinic;  MSK;  UCLA;  University of California, Davis;  University of California, San Francisco;  University of Georgia;  University of Toronto
Partners include: Delft University of Technology in The Netherlands/Center for;  NuGEN ;  University of Pittsburgh Medical School ;  University of Texas Southwestern Medical Center
Capital

Rounds: 3
Recent Fundings: Dec 2010   Mar 2005
Capital raised: 8.2M
Last Round: 5.0M
Ownership: Acquired by Takara Bio (2016 $ 50,000,000 )
Stock Symbol: WGBS
VCs include: CSK Venture Capital;  Global Asset Capital;  Malaysian Technology Development
Corporate investors: Science Futures

Last Tweets


 

Last Mentions


Overview
Record updated: May 2016
Sector: Medical
Year Founded: 2004
Headcount: 11-25 as of May 2008
Rounds: 3
Recent Fundings: Dec 2010   Mar 2005
Capital Raised: 8.2M
Last Round: 5.0M
Ownership: Acquired by Takara Bio (2016 $ 50,000,000 )
Stock Symbol: WGBS